Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 11/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358861 | 1.00 | SIGMAR1 (0.46) | SIGMAR1TMEM97DRD4DRD2CYP2D6 | |
| SCHEMBL6352482 | 0.89 | DRD4 (0.57) | DRD4DRD2 | |
| SCHEMBL6352480 | 0.89 | DRD4 (0.57) | DRD4DRD2 | |
| SCHEMBL6351467 | 0.87 | DRD4 (0.52) | DRD4DRD2 | |
| SCHEMBL6351463 | 0.87 | DRD4 (0.52) | DRD4DRD2 | |
| SCHEMBL6346741 | 0.85 | ALDH1A1 (0.46) | SIGMAR1TMEM97DRD4DRD2HRH1 | |
| SCHEMBL6353704 | 0.80 | DRD4 (0.68) | DRD4DRD2 | |
| SCHEMBL6353708 | 0.80 | DRD4 (0.68) | DRD4DRD2 | |
| SCHEMBL6357940 | 0.80 | DRD4 (0.68) | DRD4DRD2 | |
| SCHEMBL6357751 | 0.75 | DRD4 (0.47) | SIGMAR1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | SIGMAR1 1275/4885TMEM97 3004/4885DRD4 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.